Sanofi shared a post on X:
“At EAACI 2025, we’re presenting new late-breaking data from our phase 4 head-to-head study in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma.
Find out more about the results.”
More posts featuriing Sanofi on OncoDaily.